Literature DB >> 3112222

Impaired expression of high affinity interleukin 2 receptor on activated lymphocytes from patients with systemic lupus erythematosus.

H Ishida, S Kumagai, H Umehara, H Sano, Y Tagaya, J Yodoi, H Imura.   

Abstract

Peripheral lymphocytes stimulated with phytohemagglutinin (PHA-blasts) were examined for their responsiveness to exogenous interleukin 2 (IL-2). The proliferative response of PHA-blasts to IL-2 was significantly lower in patients with systemic lupus erythematosus (SLE) than in normal subjects. To clarify the reason for this defect, the expression of IL-2 receptor (IL-2R) on PHA-blasts was investigated using anti-Tac antibody and purified IL-2. Cytofluorometric analysis showed no statistical differences in the Tac positivity of PHA-blasts among normal subjects and patients with active and inactive SLE. Scatchard analysis using 125I-labeled anti-Tac monoclonal antibody revealed that the number of Tac epitopes on PHA-blasts was also not different among them. Next, the affinity of IL-2R expressed on PHA-blasts was determined by Scatchard analysis using radiolabeled IL-2 as a ligand. The number of high affinity IL-2R on the PHA-blasts was significantly decreased in patients with active and inactive SLE, as compared with normal subjects. The responsiveness of PHA-blasts to exogenous IL-2 was well correlated to the number of high affinity IL-2R, but not to the number of Tac epitopes or total IL-2R. Inasmuch as high affinity components of IL-2R are functionally active, the defective expression of high affinity IL-2R may be responsible for the T cell dysfunctions in SLE.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3112222

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  17 in total

1.  Relations between surface expression of the interleukin-2 receptor and release of the soluble form of the receptor in cultured mononuclear cells from patients with rheumatoid arthritis or systemic lupus erythematosus.

Authors:  M Itoh; Y Goto; Y Ohta; Y Goto; H Ohashi
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

2.  Responsiveness of systemic lupus erythematosus T cells to signals provided through LCA T200 (CD45) and T1 (CD5) antigens.

Authors:  J Martorell; J Font; I Rojo; R Vilella; M Ingelmo; J Vives
Journal:  Clin Exp Immunol       Date:  1989-11       Impact factor: 4.330

3.  Reversible interleukin-2 response defects in systemic lupus erythematosus.

Authors:  R J Warrington; P J Sauder; J Homik; W Ofosu-Appiah
Journal:  Clin Exp Immunol       Date:  1989-08       Impact factor: 4.330

4.  Expression of IL-2R, IL-4R, IL-6R on peripheral blood lymphocytes in systemic lupus erythematosus and correlation with disease activity: a prospective study.

Authors:  E Y Chan; C S Lau; H Zola
Journal:  J Clin Pathol       Date:  1996-08       Impact factor: 3.411

Review 5.  The cytokine network in the pathogenesis of systemic lupus erythematosus and possible therapeutic implications.

Authors:  D A Horwitz; C O Jacob
Journal:  Springer Semin Immunopathol       Date:  1994

6.  Cellular aspects of myasthenia gravis.

Authors:  S Berrih-Aknin; S Cohen-Kaminsky; D Neumann; D Safar; B Eymard; C Gaud; P Levasseur; S Fuchs; J F Bach
Journal:  Immunol Res       Date:  1988       Impact factor: 2.829

7.  A long-term immunological study of childhood onset systemic lupus erythematosus.

Authors:  C K Ting; K H Hsieh
Journal:  Ann Rheum Dis       Date:  1992-01       Impact factor: 19.103

8.  The IL-2 defect in systemic lupus erythematosus disease has an expansive effect on host immunity.

Authors:  Linda A Lieberman; George C Tsokos
Journal:  J Biomed Biotechnol       Date:  2010-06-06

Review 9.  Cytokines in systemic lupus erythematosus.

Authors:  Elaine V Lourenço; Antonio La Cava
Journal:  Curr Mol Med       Date:  2009-04       Impact factor: 2.222

10.  Serum soluble interleukin 2 receptor in systemic lupus erythematosus: effects of disease activity and infection.

Authors:  K L Wong; R P Wong
Journal:  Ann Rheum Dis       Date:  1991-10       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.